Electrophysiological effects of non-vitamin K antagonist oral anticoagulants on atrial repolarizing potassium channels

Aims: Non-vitamin K antagonist oral anticoagulants (NOACs) are widely used in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). The efficacy of NOACs has been attributed in part to pleiotropic effects that are mediated through effects on thrombin,...

Full description

Saved in:
Bibliographic Details
Main Authors: Wiedmann, Felix Tobias (Author) , Schlund, Daniel (Author) , Kraft, Manuel (Author) , Nietfeld, Jendrik (Author) , Katus, Hugo (Author) , Schmidt, Constanze (Author) , Thomas, Dierk (Author)
Format: Article (Journal)
Language:English
Published: 17 July 2020
In: Europace
Year: 2020, Volume: 22, Issue: 9, Pages: 1409-1418
ISSN:1532-2092
DOI:10.1093/europace/euaa129
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/europace/euaa129
Get full text
Author Notes:Felix Wiedmann, Daniel Schlund, Manuel Kraft, Jendrik Nietfeld, Hugo A Katus, Constanze Schmidt, and Dierk Thomas
Description
Summary:Aims: Non-vitamin K antagonist oral anticoagulants (NOACs) are widely used in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). The efficacy of NOACs has been attributed in part to pleiotropic effects that are mediated through effects on thrombin, factor Xa, and their respective receptors. Direct pharmacological effects of NOACs and cardiac ion channels have not been addressed to date. We hypothesized that the favourable clinical outcome of NOAC use may be associated with previously unrecognized effects on atrial repolarizing potassium channels. Methods and results: This study was designed to elucidate acute pharmacological effects of NOACs on cloned ion channels Kv11.1, Kv1.5, Kv4.3, Kir2.1, Kir2.2, and K2P2.1 contributing to IKr, IKur, Ito, IK1, and IK2P K+ currents. Human genes, KCNH2, KCNA5, KCND3, KCNJ2, KCNJ12, and KCNK2, were heterologously expressed in Xenopus laevis oocytes, and currents were recorded using voltage-clamp electrophysiology. Apixaban, dabigatran, edoxaban, and rivaroxaban applied at 1 µM did not significantly affect peak current amplitudes of Kv11.1, Kv1.5, Kv4.3, Kir2.1, Kir2.2, or K2P2.1 K+ channels. Furthermore, biophysical characterization did not reveal significant effects of NOACs on current-voltage relationships of study channels. Conclusion: Apixaban, dabigatran, edoxaban, and rivaroxaban did not exhibit direct functional interactions with human atrial K+ channels underlying IKr, IKur, Ito, IK1, and IK2P currents that could account for beneficial clinical outcome associated with the drugs. Indirect or chronic effects and potential underlying signalling mechanisms remain to be investigated.
Item Description:Gesehen am 21.06.2021
Physical Description:Online Resource
ISSN:1532-2092
DOI:10.1093/europace/euaa129